named programs · 3 · from sources
What they call their work
CR&T Research Grants
Provides grants to physician-scientists for research on blood cancers and other malignancies, having awarded more than $17 million since 1968.
Clinical Trials Program
Supports the development and execution of clinical trials in collaboration with pharmaceutical partners to test new therapies for MPNs.
Silver MPN Center
CR&T's flagship initiative at Weill Cornell Medicine focused on research and integrated care for myeloproliferative neoplasms, supported by over $8 million in funding.
activities · 7 groups
What they do
-
Cancer Research Funding 4 activities
- Funding blood cancer research through grantsAwards grants to support cutting-edge research in blood cancers, including myeloproliferative neoplasms (MPNs) and leukemias, often serving as the first funder for promising initiatives. Has awarded more than $17 million in grants for blood cancer research.
- Funding research leading to FDA-approved therapies and clinical advancesFinances research that has contributed to the development and FDA approval of treatments such as imatinib (Gleevec®) for chronic myeloid leukemia, and supports preclinical and clinical studies leading to new therapeutic approaches for MPNs and other cancers.
- Funding the Richard T. Silver Myeloproliferative Neoplasm (MPN) CenterProvided multi-million-dollar funding to establish and sustain the Richard T. Silver MD Myeloproliferative Neoplasm Center at Weill Cornell Medicine, including a $3.7 million gift in 2014 and over $8 million total investment. Funds patient care, clinical research, and infrastructure at the Center.
- Supporting research on lymphoma, breast cancer, and MPN treatmentsFunds and conducts research that has advanced understanding of Hodgkin’s and non-Hodgkin’s lymphoma therapies, breast cancer metastasis, anti-angiogenesis treatments, and the use of interferon alpha in MPNs, contributing to improved treatment protocols.
-
-
Biomedical Research and Innovation 2 activities
- Building clinical research infrastructure for MPNUses funding to develop clinical informatics systems, a comprehensive patient data database, biorepository of MPN specimens, and regulatory/data management teams to support long-term research at the Silver MPN Center.
- Conducting clinical and translational MPN researchCarries out research analyzing patient outcomes, including long-term studies of polycythemia vera patients, identification of predictors of treatment response, and molecular mechanisms of drug resistance, with findings published in peer-reviewed journals such as Blood.
-
-
Organizational Newsletter Production and Distribution 1 activity
- Communicating research updates and organizational newsSends a print newsletter titled CR&T News three times per year to donors and subscribers, provides email updates, and shares invitations to programs and events to keep supporters informed.
-
-
Charity Event Organization 1 activity
- Hosting annual fundraising and recognition eventsHolds the annual Cancer Survivor Hall of Fame Dinner in New York City to honor survivors, researchers, and philanthropists while raising funds for cancer research.
-
-
Rare Genetic Disease Research and Advocacy 1 activity
- Hosting educational and awareness events for patients and caregiversOrganizes the International Patient Symposium on Myeloproliferative Neoplasms every other year, providing education for patients and caregivers, with recorded sessions archived in a video library for broader access.
-
-
Organizational Governance & Leadership Development 1 activity
- Oversight and strategic guidance through Medical Advisory BoardGuides research funding priorities and organizational strategy through a Medical Advisory Board composed of leading physician-scientists in oncology and hematology.
-
-
Uncategorized 1 activity
- Distributing educational materials and wellness resourcesProvides a mindfulness coloring book for individuals with polycythemia vera and their families to reduce stress, promote relaxation, and educate about the condition.
-
financials · form 990 · fy2024
revenue
Total revenue$1.15M
Contributions & grants$776K68%
Program service revenue$00%
Investment income$511K45%
Other revenue$-140K
expenses
Total expenses$1.00M
Program expenses78%
Admin / overhead7%
Fundraising15%
Salaries & benefits$293K
Grants paid out$543K
Largest expense lineCompensation
balance sheet
Total assets$15.19M
Cash$570K
Investments$14.53M
Liabilities$301K
Net assets$14.89M
Liquid reserves180.4 mo
5 years on record · 2020–2024 · YoY revenue +11.7%
leadership · form 990 part vii · fy2024
Who runs it
paid leadership · 1
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| RICHARD TSILVER MD | Director | 40 | $120K |
board members · 17
- ADAM SILVER — Director
- AJ SHIEKMAN — Director
- AMANDA JOHNS PEREZ — Director
- ANNE TEMPLETON — Director
- CALEB SEXTON — Director
- DAVID BOULE — Director
- JEFFREY PUGLISIMD — Director
- KASIA McCORMICK — Director
- MARIA BRISBANE — Director
- MICHAEL C KEMPNER — Director
- NELSON BOXER — Director
- RAJESH SHAH — Director
- RICHARD ROSE — Director
- TERRY HERMANSON — Director
- THOMAS SILVER — Director
- TIM SILVER — Director
- TODD SHAW — Director
relationships · 33
Who they work with
- American Association for Cancer Research Partner — Provides access to peer-reviewed research, conferences, and grants in the field of cancer.
- American Cancer Society Partner — Offers access to a national network of information and support services for cancer patients and families.
- American Society of Clinical Oncology Partner — Source of patient-directed information through Cancer.net to support informed health decisions.
- American Society of Hematology Network — Professional network where research supported by CR&T is regularly presented through abstracts and publications.
- CancerCare Partner — Provides free emotional and practical support services for cancer patients, caregivers, and loved ones.
- Facebook Partner — Uses Facebook as a platform to share immediate news and updates.
- Icahn School of Medicine at Mount Sinai Partner — Affiliation of Medical Advisory Board member Edward P. Ambinder, MD.
- Johns Family Funder — Provided generous support for research on interferon-alpha and MPNs.
- Johns Hopkins University Medical Center Partner — Funds researchers at Johns Hopkins University Medical Center for clinical cancer research.
- MD Anderson Cancer Center Partner — Funds researchers at MD Anderson Cancer Center for clinical cancer research.
- MPN Advocacy and Education International Partner — Collaborates by providing access to educational and support resources for patients living with myeloproliferative neoplasms (MPNs).
- MPN Research Foundation Partner — Partner organization focused on advancing research and treatment options for myeloproliferative neoplasms (MPNs).
- Memorial Sloan-Kettering Cancer Center Partner — Dr. Scandura previously conducted research and clinical work at MSKCC, contributing to the Center's expertise in MPNs.
- Memorial Sloan-Kettering Cancer Center Partner — Funds researchers at Memorial Sloan-Kettering Cancer Center for clinical cancer research.
- NYU Grossman School of Medicine Partner — Joint affiliation of Medical Advisory Board member John P. Leonard, MD.
- NYU-Lagone Partner — Affiliation of Medical Advisory Board member John P. Leonard, MD.
- National Cancer Institute Government — Federal agency serving as the principal source for cancer research, training, and public education; referenced as a key resource for research updates and cancer centers.
- New York-Presbyterian Hospital Partner — Joint affiliation of Medical Advisory Board members Morton Coleman, MD and Mark Pasmantier, MD.
- Pharmaceutical companies Partner — Partners with pharmaceutical companies to conduct clinical trials of potential new therapies for MPNs.
- Richard T. Silver Myeloproliferative Neoplasms (MPN) Center Partner — Primary funding initiative of CR&T, focused on research and patient care for myeloproliferative neoplasms.
- Silver MPN Center Partner — Conducts joint research and clinical trials in myeloproliferative neoplasms.
- The Applebaum Foundation Funder — Provided generous support for research on interferon-alpha and MPNs.
- Twitter Partner — Uses Twitter as a platform to share immediate news and updates.
- Weill Cornell Breast Center Partner — Host institution for Medical Advisory Board members Anne Moore, MD and Alexander J. Swistel, MD.
- Weill Cornell Medical College Partner — Partnered to establish and fund the Center for the Study of Leukemia and Myeloproliferative Neoplasms, later renamed the Richard T. Silver, MD MPN Center.
- Weill Cornell Medicine Government — CR&T is affiliated with Weill Cornell Medicine, where Dr. Richard T. Silver was Professor Emeritus of Medicine and Director Emeritus of the Richard T. Silver, MD Myeloproliferative Neoplasms (MPNs) Center.
- Weill Cornell Medicine Partner — Collaborates on research involving long-term analysis of MPN patient records.
- Weill Cornell Medicine Partner — Collaborates with Weill Cornell Medicine for multidisciplinary care, research access, and clinical infrastructure.
- Weill Cornell Medicine Partner — Funds researchers at Weill Cornell Medicine for clinical cancer research.
- Weill Cornell Medicine Partner — Host institution for multiple members of the Medical Advisory Board, including the Chief Medical Advisor and other key advisors.
+ 3 more
strategies · 3
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Blood Cancer Research as a Catalyst for Broader Curesmethodology: blood-cancer-as-keystoneBy focusing investment on blood cancer research, the organization drives breakthroughs that improve understanding and treatment of multiple cancer types, because discoveries in hematologic malignancies often reveal fundamental mechanisms applicable across oncology.
- Expert-Guided, Integrated Research and Care Modelmethodology: integrated_care_research_modelBy combining clinical care with research through expert-guided, multidisciplinary centers, the organization improves patient outcomes and accelerates therapy development, because integrating real-world patient data with scientific inquiry enables faster iteration and more relevant research.
- Seed Funding for High-Potential Researchmethodology: seed_funding_for_researchBy providing early-stage capital to promising cancer research initiatives, the organization accelerates innovation and de-risks projects for future investment, because early support enables researchers to generate preliminary data and advance toward clinical impact.